Clinical trials: Migraines
Migraine
The Effects of Lasmiditan on Simulated Driving Performance - Healthy Participants
This will be a randomized, single dose, double-blind, placebo-controlled, Latin-square design with 5-period (full) crossover study with participants randomized to treatment sequences. Participants will complete all 5 Periods.
- Trial name
- NCT03012334
- Testing
- Lasmiditan, Alprazolam
- Where
- Canada
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine Headache
A Study of LY2951742 in Participants With Migraine
To assess the efficacy and safety of LY2951742 in the prevention of migraine headache in migraineurs with or without aura during 3 months of treatment.
- Trial name
- NCT01625988
- Testing
- LY2951742
- Where
- 37 sites in United States
- Volunteers
- 218 people
- Sponsor
- Eli Lilly and Company
Migraine Disorders
Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment
The purpose of this study is to evaluate the efficacy and safety of a range of oral doses of COL-144 in treating migraine headache, in order to select a dose or doses for further evaluation.
- Trial name
- NCT00883051
- Testing
- Lasmiditan
- Where
- 39 sites in Belgium, Finland and 3 more
- Volunteers
- 512 people
- Sponsor
- Eli Lilly and Company
Acute Migraine
Lasmiditan Compared to Placebo in the Acute Treatment of Migraine:
This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
- Trial name
- SAMURAI (NCT02439320)
- Testing
- Lasmiditan 100 mg, Lasmiditan 200 mg
- Where
- 92 sites in United States
- Volunteers
- 2,231 people
- Sponsor
- Eli Lilly and Company
Migraine
Oral Dexamethasone for the Treatment of Acute Migraine Recurrence in the Pediatric Emergency Department
Migraine recurrence is common amongst pediatric patients being discharged from the emergency department after treatment for migraine.
- Trial name
- NCT02794441
- Testing
- Dexamethasone
- Where
- Canada
- Volunteers
- 12 people
- Sponsor
- Children's Hospital of Eastern Ontario
Migraine
A Placebo-Controlled Adaptive Treatment Assignment Study of Intravenous COL-144 in the Acute Treatment of Migraine
This study evaluates the efficacy of a range of intravenous doses of COL-144 in the treatment of migraine headache in order to select a dose range for further studies.
- Trial name
- NCT00384774
- Testing
- Lasmiditan
- Where
- 3 sites in Finland, Germany and 1 more
- Volunteers
- 130 people
- Sponsor
- Eli Lilly and Company
Migraine
Study of Oral Lasmiditan in Participants With Normal and Impaired Renal Function
This is a multi-center, open-label, non-randomized, parallel-group, adaptive, single dose study. This study will enroll up to 32 participants using an adaptive design that can include up to 3 groups of 8 participants with…
- Trial name
- NCT03009162
- Testing
- Lasmiditan
- Where
- 2 sites in Canada
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine
Effect of Single Oral Doses of Lasmiditan When Coadministered With Single Oral Doses of Sumatriptan in Healthy Participants
This is a randomized, double-blind, three-period, cross-over study to investigate the effect of sumatriptan (Imitrex) 100 mg on the pharmacodynamics and pharmacokinetics of lasmiditan 200 mg.
- Trial name
- NCT03076970
- Testing
- lasmiditan 200 mg, Sumatriptan
- Where
- United States
- Volunteers
- 42 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine Disorders
A Study of Lasmiditan in Participants With Migraine
The purpose of this study is to measure how much of the drug gets into the blood stream and how long it takes the body to get rid of it during an acute migraine attack and also during the time between acute migraine attacks.
- Trial name
- NCT03247790
- Testing
- Lasmiditan
- Where
- 3 sites in United States
- Volunteers
- 16 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine
Pharmacokinetic Single Dose Study of Oral Lasmiditan in Participants With Normal and Impaired Hepatic Function
This is a multicenter, open-label, non-randomized, parallel-group, single dose study. This study will enroll up to 24 participants and will include 2 hepatic impaired participant groups and one group of control participants with…
- Trial name
- NCT03040479
- Testing
- lasmiditan 200 mg
- Where
- 3 sites in United States, Canada
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Migraine Headaches
The Utility of Telemedicine in the Management of Migraine
Patients will be randomly assigned to receive their follow-up care via telemedicine or in-office visits.
- Trial name
- NCT01706003
- Where
- United States
- Volunteers
- 45 people
- Sponsor
- University of Texas Southwestern Medical Center
Migraine With or Without Aura
Three Doses of Lasmiditan (50 mg, 100 mg and 200 mg) Compared to Placebo in the Acute Treatment of Migraine
This is a prospective randomized, double-blind, placebo-controlled study in participants with disabling migraine (Migraine Disability Assessment (MIDAS) score ≥ 11).
- Trial name
- SPARTAN (NCT02605174)
- Testing
- Lasmiditan 50 mg, Lasmiditan 100 mg, Lasmiditan 200 mg
- Where
- 95 sites in United States
- Volunteers
- 3,005 people
- Sponsor
- Eli Lilly and Company
Migraine, With or Without Aura
An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine
This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.
- Trial name
- NCT02873221
- Testing
- Ubrogepant, Usual Care
- Where
- 177 sites in United States
- Volunteers
- 1,254 people
- Sponsor
- Allergan
Migraine
A Randomized, Sham-controlled Study of gammaCore ® (nVNS) for Prevention of Episodic Migraine
A prospective, double-blind, randomized, sham-controlled, multicentre investigation.
- Trial name
- NCT02378844
- Testing
- gammaCore®-R
- Where
- 22 sites in Belgium, Denmark and 6 more
- Volunteers
- 477 people
- Sponsor
- ElectroCore INC
Migraine
RCT of Non-Invasive Vagus Nerve Stimulation (nVNS) With gammaCore®, for the Acute Treatment of Migraine Attacks
This study is a prospective, multi-centre, randomised, double-blind, sham-controlled investigation designed for comparison of two parallel treatment groups: gammaCore (active nVNS treatment) and a Sham device (control treatment)…
- Trial name
- NCT02686034
- Testing
- gammaCore-S
- Where
- 10 sites in Italy
- Volunteers
- 285 people
- Sponsor
- ElectroCore INC
Migraine Headache
Music Intervention on Migraine Headaches
Migraine is a frequent pathology, highly linked to anxio-depressive factors. Non-drug approaches are part of the therapeutic arsenal.
- Trial name
- CHU (NCT03763058)
- Testing
- Music Therapy
- Where
- Reunion
- Volunteers
- 20 people
- Sponsor
- Association de Musicothérapie Applications et Recherches Cliniques
Migraine
Treatment for Migraines With an Implantable Device
The purpose of this study is to evaluate the safety and effectiveness of an implantable device for difficult to treat migraine. There are a significant number of patients who have drug refractory migraine and alternative…
- Trial name
- NCT00286078
- Testing
- Precision
- Where
- 15 sites in United States
- Volunteers
- 179 people
- Sponsor
- Boston Scientific Corporation
Migraine Headache
Intravenous Fluid Therapy for the Treatment of Emergency Department Patients With Migraine Headache
The purpose of this study is to determine whether patients in the emergency department with migraine headache who are administered an intravenous fluid bolus will report greater improvement in pain scores than control patients.
- Trial name
- NCT02933060
- Testing
- Normal saline (1000 mL), Control
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- The Cooper Health System
Migraine
A Randomized Study Evaluating the Efficacy and Safety of Timolol Ophthalmic Solution as an Acute Treatment of Migraine
The purpose of this study is to assess the efficacy (headache freedom at 2 hours) of Timolol 0.5% ophthalmic solution compared to placebo in acute treatment of migraine headache.
- Trial name
- NCT03836664
- Testing
- Timolol
- Where
- United States
- Volunteers
- 25 people
- Sponsor
- University of Kansas Medical Center
Persian Gulf Syndrome
Treatment Study of Carnosine Versus Placebo in Gulf War Illness (GWI)
The purpose of this study is to perform a randomized double-blind, placebo-controlled, 12 week study of the effects of carnosine on cognitive, psychometric, autonomic, and muscle strength outcomes in 100 GWI subjects.
- Trial name
- NCT00810368
- Testing
- Carnosine
- Where
- United States
- Volunteers
- 33 people
- Sponsor
- Georgetown University